Faranoxi-a new antitumor agent.
The aim of the present study was to evaluate the antitumor activity of faranoxi experimentally and clinically. Faranoxi is a derivative of chloroethylaminophenylacetic acid containing a cytostatic group modified by oxygen in its structure. It has a broad spectrum of antitumor activity in experimental studies. One hundred eighty-eight patients with different types of malignancies were included in clinical studies. At a dosage of 90-120 mg/m2 a day for 12-15 days faranoxi is relatively well tolerated. Clinical studies demonstrate the antitumor activity of faranoxi against melanoma, lymphoma and rectal cancer. It should be noted that primary melanoma was less responsive to faranoxi compared to lymphoid metastases. Using the combination regimen FDV (faranoxi, deticene, vincristine) as treatment of melanoma, partial remission was achieved in up to 50% of the cases. Clinical trials are ongoing.
Breivis
P
P
Lithuanian Oncology Center, Vilnius.
Didziapetriene
J
J
D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000494:pharmacology* / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D004261:DNA Replication / Q000187:drug effects; D004285:Dogs; D006801:Humans; D007928:Lethal Dose 50; D051379:Mice; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D009588:Nitrogen Mustard Compounds / Q000494:pharmacology* / Q000627:therapeutic use*; D011817:Rabbits; D051381:Rats; D014407:Tumor Cells, Cultured / Q000187:drug effects
D018906:Antineoplastic Agents, Alkylating; D009588:Nitrogen Mustard Compounds; C102023:faranoxi